The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer.
Saved in:
| Title: | The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer. |
|---|---|
| Authors: | Chang TH; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tsai MF; Department of Biomedical Sciences, Da-Yeh University, Changhua, Taiwan., Wu SG; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan., Liu YN; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Wu HD; Department of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, Taipei, Taiwan., Tsai TH; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Jheng HN; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Hsu CL; Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan., Yeh PS; Department of Critical Care Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan., Shih JY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Feb 20; Vol. 16, pp. 1699471. Date of Electronic Publication: 2026 Feb 20 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1699471 |
